羚锐制药（600285.SH） 连续 5 年营收利润双增，如何看待羚锐增长的持续性？ | 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 3,311 | 3,501 | 4,157 | 4,620 | 5,111 | | 增长率 yoy（%） | 10.3 | 5.7 | 18.7 | 11.1 | 10.6 | | 归母净利润（百万元） | 568 | 723 | 839 | 973 | 1,099 | | 增长率 yoy（%） | 22.1 | 27.2 | 16.2 | 15.9 | 13.0 | | ROE（%） | 20.3 | 23.5 | 24.7 | 25.0 | 24.4 | | EPS 最新摊薄（元） | 1.00 | 1.27 | 1.48 | 1.72 | 1.94 | | P/E（倍） | 23.5 | 18.5 | 15.9 | 13.7 | 12.1 | | P/B（倍） | 4.8 | 4.3 | 3.9 | 3.4 | 3.0 ...

Investment Rating - The report maintains a strong confidence in the pharmaceutical sector, particularly in innovative drugs, predicting a reversal trend in 2025 [4] Core Viewpoints - The innovative drug sector is experiencing strong performance driven by multiple factors, including the completion of quarterly portfolio adjustments, increased policy support from the National Healthcare Security Administration (NHSA) and the National Health Commission, and significant collaborations in the industry [1][11] - The NHSA and the National Health Commission have jointly released measures to support the high-quality development of innovative drugs, which will accelerate the commercialization of domestic innovative products and create a positive cycle of profitability and strong R&D investment [20][21] - The report highlights the potential of dual/multi-target antibodies in cancer treatment and innovative drugs addressing unmet clinical needs in chronic diseases as key investment opportunities [1][4] Summary by Sections Innovative Drugs - The innovative drug sector remains the main investment line, with a focus on dual/multi-target antibodies for various cancers and chronic diseases [1][11] - AstraZeneca is in talks for a collaboration worth up to $15 billion for the AK112 drug, which has catalyzed strong performance in related stocks [1] Pharmaceutical Sector - The NHSA's new measures will direct more healthcare resources towards innovative drugs, enhancing their commercialization and profitability [20][21] - The report notes that since 2018, 149 innovative drugs have been included in the healthcare insurance directory, significantly increasing the proportion of new drugs covered [22] Biologics - Changchun High-tech's new drug, Vuxin Qibai monoclonal antibody, has been approved for treating acute gout arthritis, marking a significant advancement in biologics [29][34] - The drug shows rapid onset of action and a substantial reduction in recurrence risk, highlighting its clinical significance [33][34] Traditional Chinese Medicine - Lingrui Pharmaceutical's new indication for its nasal spray is expected to boost sales, with ongoing efforts to expand hospital coverage and OTC sales [38][41] Medical Devices - The report emphasizes policy support for high-end medical devices, predicting accelerated commercialization in various segments such as medical robots and AI [3][4] Medical Services - Recent policies to enhance maternity benefits are expected to stimulate demand in related services [3][4]

证券代码：600285 证券简称：羚锐制药 公告编号：2025-028 号 河南羚锐制药股份有限公司 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，河南羚锐制药股份有限公司（以下简称"公司"）子公司银谷制药有 限责任公司（以下简称"银谷制药"）收到国家药品监督管理局核准签发的《药 品注册证书》，批准银谷制药自主研发的 1 类创新药苯环喹溴铵鼻喷雾剂新增适 应症，用于改善感冒引起的流涕、鼻塞、鼻痒和喷嚏症状。现将相关情况公告如 下： 一、 药品的基本情况 药品名称：苯环喹溴铵鼻喷雾剂 剂型：喷雾剂 规格：5ml:5mg,每瓶 50 喷,每喷含苯环喹溴铵 90μg；10ml:10mg,每瓶 100 喷,每喷含苯环喹溴铵 90μg 注册分类：化学药品 2.4 类 证书编号：2025S01880、2025S01881 处方药/非处方药：处方药 审批结论：据《中华人民共和国药品管理法》及有关规定，经审查，本品符 合药品注册的有关要求，批准增加适应症，新增适应症为："本品适用于改善感 冒引起的流涕、鼻塞 ...

智通财经7月1日电，羚锐制药(600285.SH)公告称，子公司银谷制药收到国家药品监督管理局核准签发 的《药品注册证书》，批准苯环喹溴铵鼻喷雾剂新增适应症，用于改善感冒引起的流涕、鼻塞、鼻痒和 喷嚏症状。该药品此前已获批上市，用于改善变应性鼻炎引起的相关症状，并已进入《中国变异性鼻炎 诊断和治疗指南》。苯环喹溴铵鼻喷雾剂作为国内唯一获批适用于变应性鼻炎的鼻用抗胆碱能药物，市 场规模约为54亿元。此次新增感冒适应症，作为非激素用药，是国内首个M受体拮抗剂用于感冒后鼻部 症状的鼻喷剂药品，有利于进一步提升产品力。研发投入累计约3,597万元。 羚锐制药：子公司银谷制药苯环喹溴铵鼻喷雾剂新增感冒适应症 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in terms of profit is outstanding, with a revenue of 3.501 billion yuan in 2024 (up 5.72% year-on-year) and a net profit attributable to shareholders of 722.55 million yuan (up 27.19% year-on-year) [2] - In Q1 2025, the company achieved a revenue of 1.021 billion yuan (up 12.29% year-on-year, up 37.62% quarter-on-quarter) and a net profit of 217 million yuan (up 13.89% year-on-year, up 45.83% quarter-on-quarter) [2] - The company is a leading player in the traditional Chinese medicine patch market, with a strong performance in core products and a promising growth outlook due to recent acquisitions [6][7] Summary by Sections Financial Performance - In 2024, the company reported a gross margin of 75.82% and a net margin of 20.64%, with improvements in gross margins across various product lines [6] - The company plans to enhance its product pipeline through the acquisition of Yingu Pharmaceutical for 704 million yuan, which is expected to provide significant synergies and fill gaps in its product offerings [6][7] Revenue Breakdown - The revenue from patches reached 2.115 billion yuan in 2024 (up 3.35% year-on-year), while tablets saw a significant increase of 35.60% year-on-year, reaching 355 million yuan [6] - The core product Tongluo Qutong Gao is expected to generate over 1.2 billion yuan in revenue, with double-digit growth anticipated for the "Two Tigers" series [6] Earnings Forecast - The company is expected to achieve net profits of 826.30 million yuan, 951.24 million yuan, and 1.07982 billion yuan for the years 2025, 2026, and 2027 respectively, with corresponding EPS of 1.46, 1.68, and 1.90 yuan [7]

Core Insights - The company reported a revenue of 3.501 billion yuan for 2024, representing a year-on-year increase of 5.7%, and a net profit attributable to shareholders of 723 million yuan, up 27.2% year-on-year [1] - In Q1 2025, the company achieved a revenue of 1.021 billion yuan, a 12.3% increase year-on-year, with a net profit of 217 million yuan, reflecting a 13.9% year-on-year growth [1] Business Performance - The orthopedic segment showed steady growth, with revenue of approximately 2.32 billion yuan in 2024, a 9.5% increase year-on-year, and a gross margin improvement of 3.9 percentage points [2] - The sales of the Tongluo Pain Relief Plaster exceeded 1 billion yuan, and the "Two Tigers" series products sold over 1 billion patches, indicating strong brand strength [2] - The cardiovascular segment generated about 450 million yuan in revenue, a 3.3% year-on-year increase, with the Peiyuan Tongnao capsule gradually gaining market traction [2] Product Expansion and Acquisitions - The tablet segment saw significant growth, with revenue of approximately 360 million yuan, a 35.6% increase year-on-year, driven by strong sales of Danlu Tongdu tablets [3] - The company acquired 90% of Yingu Pharmaceutical for 704 million yuan, enhancing growth potential and filling gaps in its nasal spray product line [3] - The acquisition is expected to strengthen the company's hospital sales capabilities and enhance the sales channels for Yingu's products [3] Dividend Policy - The company announced a cash dividend of 0.90 yuan per share for 2024, totaling approximately 510 million yuan, which represents 70.64% of the net profit attributable to shareholders [3] Financial Forecast - The orthopedic business is expected to benefit from an aging population, with projected revenues of 4.2 billion yuan, 4.68 billion yuan, and 5.23 billion yuan for 2025-2027, reflecting year-on-year growth rates of 19.9%, 11.6%, and 11.7% respectively [4] - The net profit attributable to shareholders is forecasted to be 840 million yuan, 950 million yuan, and 1.07 billion yuan for the same period, with growth rates of 15.9%, 13.1%, and 13.0% respectively [4] - The estimated earnings per share (EPS) for 2025-2027 are projected to be 1.48 yuan, 1.67 yuan, and 1.89 yuan, with corresponding price-to-earnings (PE) ratios of 15, 13, and 12 times [4]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [4][11]. Core Insights - The company reported a revenue of 3.501 billion RMB in 2024, a year-on-year increase of 5.7%, and a net profit attributable to shareholders of 723 million RMB, up 27.2% year-on-year [2]. - The acquisition of Yingu Pharmaceutical for 704 million RMB is expected to enhance the company's growth potential by filling product gaps and improving sales capabilities [3]. - The orthopedic product segment continues to show robust growth, with revenue reaching approximately 2.32 billion RMB in 2024, a 9.5% increase year-on-year [3]. Summary by Sections Performance Review - In Q1 2025, the company achieved a revenue of 1.021 billion RMB, reflecting a 12.3% year-on-year growth, and a net profit of 217 million RMB, up 13.9% year-on-year [2]. Operational Analysis - The orthopedic segment's revenue growth is attributed to an aging population and improved product margins, with a gross margin increase of 3.9 percentage points [3]. - The company plans to distribute a cash dividend of 0.90 RMB per share, totaling approximately 510 million RMB, which represents 70.64% of the net profit for 2024 [3]. Profit Forecast and Valuation - Revenue projections for 2025-2027 are estimated at 4.196 billion RMB, 4.683 billion RMB, and 5.231 billion RMB, with respective year-on-year growth rates of 19.9%, 11.6%, and 11.7% [4]. - The expected net profit for the same period is projected to be 840 million RMB, 950 million RMB, and 1.07 billion RMB, with growth rates of 15.9%, 13.1%, and 13.0% respectively [4].

国金证券股份有限公司袁维近期对羚锐制药（600285）进行研究并发布了研究报告《业绩稳健增长，期待 并购整合进展》，给予羚锐制药买入评级。 羚锐制药 业绩简评 2025年4月25日，公司发布2024年年度报告。2024年公司实现收入35.01亿元(同比+5.7%)，实现归母净利润 7.23亿元(同比+27.2%)，实现扣非归母净利润6.42亿元(同比+20.2%)。 公司同时发布2025年一季报。2025年Q1公司实现收入10.21亿元(同比+12.3%)，实现归母净利润2.17亿元 (同比+13.9%)，实现扣非归母净利润2.04亿元(同比+12.4%)。 经营分析 盈利预测、估值与评级 公司骨科业务有望受益于老龄化，持续稳健增长，收购银谷有望实现内生外延双轮驱动。考虑银谷并表， 预计公司25-27年营收分别42.0/46.8/52.3亿元，分别同比增长19.9%/11.6%/11.7%，预计公司25-27年归母净 利润分别8.4/9.5/10.7亿元，分别同比增长15.9%/13.1%/13.0%，25-27年EPS分别为1.48/1.67/1.89元，现价对 应PE分别为15/13/12倍，维持"买入" ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [4][11]. Core Insights - The company reported a revenue of 3.501 billion RMB in 2024, a year-on-year increase of 5.7%, and a net profit attributable to shareholders of 723 million RMB, up 27.2% year-on-year [2]. - The acquisition of Yingu Pharmaceutical for 704 million RMB is expected to enhance the company's growth potential by filling product gaps and improving sales capabilities [3]. - The orthopedic product segment continues to show robust growth, with revenues reaching approximately 2.32 billion RMB in 2024, a 9.5% increase year-on-year [3]. Summary by Sections Performance Review - In Q1 2025, the company achieved a revenue of 1.021 billion RMB, reflecting a 12.3% year-on-year growth, and a net profit of 217 million RMB, up 13.9% year-on-year [2]. Operational Analysis - The orthopedic segment's revenue growth is attributed to an aging population and improved product margins, with a gross margin increase of 3.9 percentage points [3]. - The company plans to distribute a cash dividend of 0.90 RMB per share, totaling approximately 510 million RMB, which represents 70.64% of the net profit for 2024 [3]. Profit Forecast and Valuation - Revenue projections for 2025-2027 are estimated at 4.196 billion RMB, 4.683 billion RMB, and 5.231 billion RMB, with respective year-on-year growth rates of 19.9%, 11.6%, and 11.7% [4]. - The expected net profit for the same period is forecasted to be 840 million RMB, 950 million RMB, and 1.07 billion RMB, with growth rates of 15.9%, 13.1%, and 13.0% respectively [4].

涉及总金额4 0 8 . 5 3亿元人民币。 作者 | 私募通 来源 | 决策投资圈 （ID：PEDATAMAX） 清科创业（0 1 9 4 5 .HK）旗下私募通统计：截至本周五下午，募资、投资、上市和并购共 1 4 8起事件，涉及总金额4 0 8.53亿人民币。从交易金额来看，本周金额较大事件是： 2 0 25年3月4日，全国社会保障基金理事会投资国投电力控股股份有限公司7 0 . 0 0亿人民 币。从交易事件地域分布看，目前主要分布在上海市、北京市和江苏省，占比为上海市 2 0 .5%，北京市1 6 . 7%，江苏省14.1%。 01 本周募资情况 本周新登记股权投资基金管理人共计0家，取消备案登记4家，全年截至目前累计股权投 资基金管理人数量为11家。本周新增备案基金数量为70只，规模总计1 4 6 . 5 1亿元，本周 备案基金募资最多的为合肥市包河区产发创业投资合伙企业（有限合伙）和绵阳涪江新 兴股权投资合伙企业（有限合伙），募集20.00亿人民币。全年截至目前累计股权投资备 案基金数量为7 0 1只，规模总计5705.25亿元。（2025年2月2 8日- 2 0 2 5年3月6日） 投资金额TO ...